CellCept(R) registry data demonstrated superior long-term organ transplan...( Boston May 16 2004 - Data presented t...),Health

Boston, May 16, 2004 - Data presented today at a top U.S. transplant meeting demonstrated better patient and graft (organ) survival in liver and kidney transplant patients taking CellCept (mycophenolate mofetil) compared to those receiving treatment regimens not including CellCept. These findings revealed a significant improvement in outcomes over previous standards of transplantation care and are part of a still-growing body of data on CellCept, which received FDA approval in 1995.

The data were presented at the American Transplant Congress and focused on the results of two separate studies. In total, the studies looked at nearly 35,000 organ recipients from the Scientific Registry of Transplant Recipients (SRTR), of which more than 25,000 received CellCept-based treatment regimens. The two studies covered six and fours years, respectively, of post-surgical outcomes.

"CellCept has had a significant effect on the improvement of organ transplant outcomes over the past nine years," said Herwig-Ulf Meier-Kriesche, M.D., associate professor, University of Florida College of Medicine and lead author of the renal transplantation study. "Data such as these are critical to increasing our understanding of the full scope of treatment options for transplant recipients. The more long-term information physicians have, the more the standard of care will continue to improve."

On average, 70 people receive transplants from either a living or deceased donor every day and over 25,500 transplants are performed each year. Currently, there are more than 84,000 people on the nation's organ transplant waiting list.

"Over the past decade, CellCept has helped to improve the lives of thousands of kidney, liver and heart transplant recipients," said Robert Gordon, M.D., medical director of organ transplantation at Roche. "The wealth of data and positive experiences using CellCept further supports its use in kidney, liver and heart transplantation and demons
'"/>

Contact: Julio Cantre
Julio.Cantre@ketchum.com
917-204-0599
Ketchum
17-May-2004

Page: 1 2 3 4 5
Related medicine news :

1. Womens health research registry aims to improve womens health for future generations
2. Potential treatment for Fragile X Syndrome demonstrated in fruit fly model
3. Long-term study demonstrated ADDERALL XR is an effective option to treat adolescents with ADHA
4. Wavefront LASIK demonstrated superior to conventional LASIK
5. Effectiveness of safer smallpox vaccine demonstrated against monkeypox
6. Landmark antidepressant analysis demonstrated significant efficacy of Effexor®/Effexor XR
7. Eficiency, feasibility of antiretroviral therapy in Africa demonstrated in IRD-coordinated surveys
8. Spiral waves break hearts: Importance of communication between cardiac cells is demonstrated
9. First link demonstrated between multiple concussions, neuropsychological deficits in college athletes
10. Kinder, gentler procedure gives superior results for stem cell transplants
11. Therapy, medication combination superior for children with obsessive-compulsive disorder